Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences

Circulation

Volumn 109, Issue 24, 2004, Pages 3022-3028

  Greenfield, Jerry R ^a,b   Samaras, Katherine ^a,b   Jenkins, Arthur B ^c   Kelly, Paul J ^d   Spector, Tim D ^e   Gallimore, J Ruth ^f   Pepys, Mark B ^f   Campbell, Lesley V ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d Orchid Cellmark   (United States)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Inflammation; Lipids; Obesity; Syndrome X

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BEHAVIOR; BLOOD PRESSURE; BODY FAT; CARDIOVASCULAR DISEASE; CENTRAL ABDOMINAL FAT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENVIRONMENTAL FACTOR; FEMALE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MONOZYGOTIC TWINS; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3042654996     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000130640.77501.79     Document Type: Article

References (62)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 240:115-126.
2. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
3. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
4. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
5. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes. 2003;52:1799-1805.
6. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Ausburg Cohort Study. Arch Intern Med. 2003;163:93-99.
7. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol. 2003;92(suppl):18J-26J.
8. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
9. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847-850.
10. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-674.
11. Danesh J, Muir J, Wong Y-K, et al. Risk factors for coronary heart disease and acute-phase proteins: a population-based study. Eur Heart J. 1999;20:954-959.
12. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
13. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
14. Koenig W, Sund M, Frolich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged males: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort Study, 1984-1992. Circulation. 1999;99:237-242.
15. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312:1061-1065.
16. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. 2001;104:145-150.
17. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.
18. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-1839.
19. Manns PJ, Williams DP, Snow CM, et al. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Hum Biol. 2003;15:91-100.
20. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633-638.
21. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol. 1997; 24:782-784.
22. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001;154:681-689.
23. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of C-reactive protein. Cardiovasc Res. 2002;53:1029-1034.
24. MacGregor AJ, Gallimore JR, Spector TD, et al. Genetic effects on baseline values of C-reactive protein and serum amyloid A protein: a comparison of monozygotic and dizygotic twins. Clin Chem. 2004;50: 130-134.
25. Samaras K, Spector TD, Nguyen TV, et al. Independent genetic factors determine the amount and distribution of fat in women after the menopause. J Clin Endocrinol Metab. 1997;82:781-785.
26. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002;162:217-219.
27. Szalai AJ, McCrory MA, Cooper GS, et al. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immunol. 2002;3:14-19.
28. Brull DJ, Serrano N, Zito F, et al. A polymorphism in the human CRP gene influences basal and stimulated CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Atherosclerosis. 2003;168:192. Abstract.
29. Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis. 2003;169:279-282.
30. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta. 1981;117:13-23.
31. Samaras K, Kelly PJ, Chiano MN, et al. Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins. Ann Intern Med. 1999;130:873-882.
32. Greenfield JR, Samaras K, Jenkins AB, et al. Moderate alcohol consumption, estrogen replacement therapy and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator? Diabetes Care. 2003;26:2734-2740.
33. WHO Expert Committee on Biological Standardization, 37th Report. WHO Technical Report Series 760. Geneva, Switzerland: World Health Organization; 1987:21-22.
34. Wilkins J, Gallimore JR, Moore EG, et al. Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin Chem. 1998;44: 1358-1361.
35. Samaras K, Kelly PJ, Chiano MN, et al. Genes versus environment: the relationship between dietary fat and total and central abdominal fat. Diabetes Care. 1998;21:2069-2076.
36. Greenfield JR, Samaras K, Jenkins AB, et al. Moderate alcohol consumption, dietary fat composition and abdominal obesity: evidence for gene-environment interaction. J Clin Endocrinol Metab. 2003;88: 5381-5386.
37. Yeh ETH, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-372.
38. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105: 564-569.
39. Weyer C, Yudkin JS, Stehouwer CDA, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002;161:233-242.
40. Sites CK, Toth MJ, Cushman M, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin stimulated-glucose disposal. Fertil Steril. 2002;77:128-135.
41. Barinas-Mitchell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol. 2001;153:1094-1101.
42. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25:1327-1331.
43. Bastard J-P, Jardel C, Delattre J, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99:2221-2222.
44. Stauffer BL, Hoetzer GL, Smith DT, et al. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J Appl Physiol. 2004;96:143-148.
45. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961-967.
46. Greenfield JR, Samaras K, Chisholm DJ, et al. Regional intra-subject variability in abdominal adiposity limits usefulness of computed tomography. Obes Res. 2002;10:260-265.
47. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799-1804.
48. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol. 2001;21:968-970.
49. Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003;88:1055-1058.
50. McLaughlin T, Abbasi F, Lamendola C, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908-2912.
51. Hanusch-Enserer U, Cauza E, Spak M, et al. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord. 2003;27: 355-361.
52. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23: 1042-1047.
53. Laimer M, Ebenbichler CF, Kaser S, et al. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord. 2002;26:659-662.
54. Kazumi T, Kawaguchi A, Hirano T, et al. C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism. 2003;52:1113-1116.
55. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab. 2003;88:2470-2478.
56. Frölich M, Muhlberger N, Hanke H, et al. Markers of inflammation in women on different hormone replacement therapies. Ann Med. 2003;35: 353-361.
57. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
58. Imhof A, Froehlich M, Brenner H, et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet. 2001;357:763-767.
59. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443-447.
60. Stewart SH, Mainous AG 3rd, Gilbert G. Relation between alcohol consumption and C-reactive protein levels in the adult US population. J Am Board Fam Pract. 2002;15:437-442.
61. Sierksma A, van der Gaag MS, Kluft C, et al. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels: a randomized, diet-controlled intervention study. Eur J Clin Nutr. 2002;56: 1130-1136.
62. Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med. 1995;332:1245-1250.